cd38 car-t cells
Cell therapyexperimental
Clinical trial activity
6 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2017 (NCT04351022)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Immunity, passive
CD38 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05995041 | Phase 1 | Oct 31, 2023 | Shenzhen Geno-Immune Medical Institute |
| NCT05239689 | Early Phase 1 (Phase 1) | Feb 28, 2022 | Yake Biotechnology Ltd., Zhejiang University |
| NCT03754764 | Phase 1/Phase 2 (Phase 2) | Nov 23, 2018 | People's Liberation Army of China |
| NCT03473457 | N/A | Apr 1, 2018 | Southern Medical University, Sun Yat-Sen University |
| NCT03473496 | N/A | Mar 1, 2018 | Southern Medical University, Sun Yat-Sen University |
| NCT04351022 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2017 | Soochow University |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Southern Medical University | Academic/Hospital | 2 | 2 | 1 | 2018 |
| Sun Yat-Sen University | Academic/Hospital | 2 | 0 | 1 | 2018 |
| People's Liberation Army of China | Government | 1 | 1 | 1 | 2018 |
| Shenzhen Geno-Immune Medical Institute | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Soochow University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Yake Biotechnology Ltd. | Government | 1 | 0 | 1 | 2022 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2022 |
7 organizations
Page 1 / 1